Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid

Campo, Paula Lázaro del; Lopez, Andres Ramirez; Cruz-Benito, Beatriz de la; Arias, Raquel De Paz; Álvarez, Teresa de Soto; Vadillo, Irene Sánchez; Barbier, Karem Humala; Pérez, Eduardo García; Ortas, Abel Dos Santos; Guía, Ana López de la; Kabat, Mercedes Gasior; Tello, Patricia Baltasar; Yuste, Vı́ctor J.; Albendea, Miguel Ángel Canales

doi:10.1080/17474086.2021.1858789

Cited by 6 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This left 57 full-text articles to be assessed for eligibility. Thirty-six of these studies met our eligibility criteria [ 16 , 21 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ]. These studies included a total of 2011 patients, 516 of whom underwent SCT.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis

Kamal,

Baudo,

Joseph

et al. 2024

Healthcare

View full text Add to dashboard Cite

This systematic review and meta-analysis aims to identify the outcomes of stem cell transplant (SCT) patients during the COVID-19 era. Pooled event rates (PER) were calculated, and meta-regression was performed. A random effects model was utilized. In total, 36 eligible studies were included out of 290. The PER of COVID-19-related deaths and COVID-19-related hospital admissions were 21.1% and 55.2%, respectively. The PER of the use of hydroxychloroquine was 53.27%, of the receipt of immunosuppression it was 39.4%, and of the use of antivirals, antibiotics, and steroids it was 71.61%, 37.94%, and 18.46%, respectively. The PER of the time elapsed until COVID-19 infection after SCT of more than 6 months was 85.3%. The PER of fever, respiratory symptoms, and gastrointestinal symptoms were 70.9, 76.1, and 19.3%, respectively. The PER of acute and chronic GvHD were 40.2% and 60.9%, respectively. SCT patients are at a higher risk of severe COVID-19 infection and mortality. The use of dexamethasone improves the survival of hospitalized SCT patients with moderate to severe COVID-19 requiring supplemental oxygen or ventilation. The SCT patient group is a heterogeneous group with varying characteristics. The quality of reporting on these patients when infected with COVID-19 is not uniform and further prospective or registry studies are needed to better guide clinical care in this unique setting.

show abstract

Section: Resultsmentioning

confidence: 99%

“… Pooled event rate for the use of hydroxychloroquine [ 16 , 28 , 29 , 31 , 37 , 38 , 40 , 41 , 42 , 45 , 52 , 56 , 57 ]. …”

Section: Figurementioning

confidence: 99%

Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis

Kamal,

Baudo,

Joseph

et al. 2024

Healthcare

View full text Add to dashboard Cite

show abstract

“…A number of published works to the similar topic point to decreased transplant activity in HSCT centers around the world during the COVID-19 pandemic [7][8][9][10][11][12]. We tried, however, to keep the same transplant activity.…”

Section: Discussionmentioning

confidence: 99%

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Siniaev¹,

Popova²,

Rogacheva³

et al. 2022

CTT

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for oncological, hematological and non-malignant disorders. Despite global trend for a decrease of transplantation activity in view of the COVID-19 pandemic, we tried to maintain it by taking preventive measures and optimizing infection control in our center. Patients and methodsThis is an observational study. We collected the performance data of our transplant center from April 2020 to July 2021, i.e., during two waves of the pandemic. The main objectives were to study the influence of COVID-19 pandemic on the workflow of the HSCT center, including morbidity among employees and HSCT recipients, as well as on the transplant activity. ResultsThe first case of COVID-19 infection in St. Petersburg was recorded on March 8, 2020. On March 30, 2020, a national lockdown had been imposed in the Russian Federation. The second wave of COVID-19 started in October 2020. Weekly screening of staff and patients was the main diagnostic tool, in addition to the governmental requirements. In sum, a total of 21702 PCR tests for SARS-CoV-2 were performed over the study period. As for July 1, 2021, 69.7% of employees became immune to the virus, due to previous COVID-19 disease, or by vaccination. In 2020, we managed to perform 419 HSCT, including 136 autologous and 283 allogeneic transplants. For comparison, 415 HSCTs were carried out in 2019, with 144 autologous and 271 allogeneic transplants. In 2020, the HSC donorship was shifted towards unrelated donors from the Russian Registry and haploidentical donors. Incidence of COVID-19 among HSCT recipients between April 2020 and July 2021 was 7.3% (n=39), being 8.6% (n=31) after allogeneic HSCT, and 4.5% (n=8) following auto-HSCT. The median age of patients with COVID-19 was 27 years (4-66). The median term for the COVID-19 onset was 68 days post-transplant (-1 to +2093). In most patients -29 (74.3%) the HCT CI comorbidity index at the time of transplantation was 0. The stem cell source were either peripheral blood stem cells (n=22, 56.4%), or bone marrow (n=17, 43.6%). Most of the patients achieved complete remission of the underlying disease at the time of HSCT (n=30, 76.9%). The overall 100-day survival rate among HSCT recipients since the diagnosis of the COVID-19 was 79.5% (95% CI 0.609 -0.884). The mortality rate was 20.5% (n=8). The causes of death were as follows: COVID-19 -50% (n=4); secondary infectious complications, 25% (n=2); relapse of the underlying disease, 12.5% (n=1);

show abstract

“…25 Some individual hospitals have also adopted a COVID-19 screening approach prior to admitting lymphoma patients and donor or performing on-site clinical assessment. 72 During the circulation of the Delta variant, the EBMT recommended excluding donors with COVID-19 for 3 months, while the ASTCT and World Marrow Donor Association (WMDA), suggested excluding donors for at least 28 days.…”

Section: Treatment Management Recommendationsmentioning

confidence: 99%

“…To minimize the risk to the patient, the EBMT recommends home isolation 14 days before the start of the CAR‐T cell transplant conditioning and that unnecessary clinic visits be avoided 25 . Some individual hospitals have also adopted a COVID‐19 screening approach prior to admitting lymphoma patients and donor or performing on‐site clinical assessment 72 . During the circulation of the Delta variant, the EBMT recommended excluding donors with COVID‐19 for 3 months, while the ASTCT and World Marrow Donor Association (WMDA), suggested excluding donors for at least 28 days.…”

Section: Treatment Management Recommendationsmentioning

confidence: 99%

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Elliott

Hensen

Haupt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) pandemic has dramatically impacted the health risk and management of patients with lymphoma. Clinical evaluations on the impact of COVID-19 on lymphoma patients are currently limited however, reports have shown a correlation with specific variants and more severe COVID-19 complications and higher mortality rates relative to other disease states and age-matched populations. During peak pandemic periods this created a concerning management problem for clinicians and raised the question of how different immunocompromised states increase COVID-19-associated risk and provided

show abstract

Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid

Cited by 6 publications

References 13 publications

Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis

Characteristics and Outcomes of Stem Cell Transplant Patients during the COVID-19 Era: A Systematic Review and Meta-Analysis

Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Contact Info

Product

Resources

About